Publications by authors named "B C Eu"
Background: Modest weight and lipid changes have been observed in cabotegravir plus rilpivirine long-acting (CAB+RPV LA) Phase 3/3b studies. The SOLAR study included standardized evaluations of weight and metabolic changes in people living with HIV switching to CAB+RPV LA dosed every 2 months (Q2M) vs. continuing bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF).
View Article and Find Full Text PDFArticle Synopsis
- The study highlights the growing trend of prescribing testosterone for gender affirming hormone therapy (GAHT) in Australia, primarily conducted by general practitioners (GPs), as detailed in AusPATH guidelines.
- A cross-sectional study named PUSH! Audit was conducted in 9 GP clinics across 5 cities, comparing GAHT patients with cisgender men receiving testosterone for deficiency.
- Results indicated that GAHT patients were generally younger, had notable health concerns like smoking and anxiety, but showed high monitoring levels and low adverse effects, making GAHT effective in general practice.
Article Synopsis
- The SOLAR study compared the effectiveness of a long-acting injection treatment (CAB + RPV LA) to a daily oral regimen (BIC/FTC/TAF) for HIV over 12 months, showing that the injection was just as effective in managing the virus.
- Out of 670 participants, those who switched to CAB + RPV LA reported significantly higher treatment satisfaction and better mental health outcomes compared to those who continued with BIC/FTC/TAF.
- 90% of participants preferred the long-acting injection, indicating a positive shift in perceptions regarding HIV treatment by reducing psychological challenges associated with daily medication regimens.
Introduction: To ascertain the adverse health outcomes experienced by those using prescribed testosterone and non-prescribed anabolic-androgenic steroids presenting to general practitioner (GP) clinics.
Methods: Retrospective clinical audit from nine GP clinics in major metropolitan areas across three Australian states. Data included demographic and individual characteristics (age, sexuality, body mass index, smoking status and HIV status); performance and image-enhancing drug use (type, reasons for use, patient-reported adverse effects); and blood biochemistry measurements (lipid profiles, liver function tests and red blood cell tests).
Hypogonadism can result following anabolic steroid abuse. The duration and degree of recovery from anabolic steroid-induced hypogonadism (ASIH) is immensely variable, and there is a paucity of prospective controlled data characterising the trajectory of natural recovery following cessation. This poses difficulties for users trying to stop androgen abuse, and clinicians wanting to assist them.
View Article and Find Full Text PDF